IDEXX Laboratories, Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Vanguard Real Estate Index Fund ETF trades at $90.65 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is the larger of the two by market cap, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| IDXX | VNQ | |
|---|---|---|
Market Cap | $40.43B | $70.80B |
Volume | 692,164 | 6,073,580 |
Sector | Health | — |
52-Week High | $766.68 | $100.95 |
52-Week Low | $504.70 | $87.00 |
Typical Hold Time | 46 Days | 113 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
VNQ trades at $89.35, up 0.74% today, but faces bearish technical signals with moving averages indicating selling pressure. The ETF has declined nearly 10% recently amid rising Treasury yields and Fed rate hikes, eroding its income appeal versus safer alternatives. Recent institutional buying by State Street Corp and Envestnet suggests some see value at current levels, while news highlights sector headwinds from interest rate sensitivity and oversupply concerns in certain real estate segments.
Outlook remains challenged by rising rates compressing REIT valuations, though contrarian investors see opportunity in discounted sector exposure. Key risks include prolonged high interest rates, economic slowdown impacting property demand, and competition from Treasury yields. The dividend yield advantage has narrowed significantly, requiring careful assessment of total return potential versus rate-sensitive alternatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →